Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. discovers and develops novel antibody immunotherapies that help immune system to attack diseased cells. It focuses on developing a pipeline of product candidates (immunomodulators) for the treatment of cancer and inflammatory diseases. The company was formerly known as Enumeral Biomedical Corp. and changed its name to Enumeral Biomedical Holdings, Inc. in August 2014. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
One Kendall Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Total Annual Compensation: $250.0K
Co-Founder and Executive Chairman
Total Annual Compensation: $200.0K
Vice President of Business Development and Secretary
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2013.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings, Inc. and Merck Sharp & Dohme Corp. Form Collaboration for Predicting Clinical Drug Response with Human-Driven Immune Profiling Platform
Dec 18 14
Enumeral Biomedical Holdings, Inc. announced that it has signed an oncology-focused collaborative study agreement with Merck Sharp & Dohme Corp. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies.
Enumeral Biomedical Holdings, Inc. Appoints Paul Sekhri to its Board of Directors
Dec 18 14
On December 16, 2014, Paul Sekhri was appointed to the board of directors of Enumeral Biomedical Holdings, Inc. Mr. Sekhri will serve as a Class III director of Enumeral for a term expiring in 2017 or until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Sekhri was appointed to the Board in accordance with the provisions of that certain Voting Agreement, dated as of July 31, 2014, by and
among Enumeral and certain stockholders named therein, and is designated the ‘Montrose Director’ by Montrose Capital Limited and EDI Financial, Inc. Mr. Sekhri has not been named to any committees of the Board at the time of his appointment.
Enumeral Biomedical Holdings, Inc. Appoints Robert L. Van Nostrand to its Board of Directors
Dec 4 14
Enumeral Biomedical Holdings, Inc. announced that it has appointed Robert L. Van Nostrand to its board of directors. Most recently, Mr. Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. Mr. Van Nostrand currently serves on the boards of several other publicly traded biotechnology companies, including Metabolix, where he is chairman, Achillion Pharmaceuticals and Intra-Cellular Therapies. Mr. Van Nostrand also serves as the chairman of the audit committee for each of these companies. In addition, Mr. Van Nostrand serves on the board of directors of the Biomedical Research Alliance of New York.
Similar Private Companies By Industry
Recent Private Companies Transactions